Citation:

Hagiwara, S., G. Paoli, P. Price, M. Gwinn, A. Guiseppi-Elie, P. Farrell, B. Hubbell, D. Krewski, AND R. Thomas. A value of information framework for assessing the trade-offs associated with uncertainty, duration, and cost of chemical toxicity testing. RISK ANALYSIS. Blackwell Publishing, Malden, MA, 43(3):498-515, (2023). https://doi.org/10.1111/risa.13931

Impact/Purpose:

This paper presents the results of an ongoing project to develop a decision framework that objectively and transparently define prefered toxicity-testing methodologies. The framework was based on the concept of Value of Information. This guidance will support programs for the testing for the large numbers of untested chemicals in commercial use.

Description:

A number of investigators have explored the use of value of information (VOI) analysis to evaluate alternative information collection procedures in diverse decision-making contexts. This paper presents an analytic framework for determining the value of toxicity information used in risk-based decision making. The framework is specifically designed to explore the trade-offs between cost, timeliness, and uncertainty reduction associated with different toxicity-testing methodologies. The use of the proposed framework is demonstrated by two illustrative applications which, although based on simplified assumptions, show the insights that can be obtained through the use of VOI analysis. Specifically, these results suggest that timeliness of information collection has a significant impact on estimates of the VOI of chemical toxicity tests, even in the presence of smaller reductions in uncertainty. The framework introduces the concept of the expected value of delayed sample information, as an extension to the usual expected value of sample information, to accommodate the reductions in value resulting from delayed decision making. Our analysis also suggests that lower cost and higher throughput testing also may be beneficial in terms of public health benefits by increasing the number of substances that can be evaluated within a given budget. When the relative value is expressed in terms of return-on-investment per testing strategy, the differences can be substantial.

URLs/Downloads:

Record Details: